New Raltegravir Potassium Merck Agreement Proves to be a Major Improvement Over the Status Quo

Raltegravir potassium CAS 871038-72-1

Product name and CAS#: Raltegravir potassium CAS# 871038-72-1

Raltegravir potassium is a human immunodeficiency virus integrase strand transfer inhibitor. The drug is soluble in water and slightly soluble in ethanol and methanol as well. The pharmaceutically acceptable salt has been approved for the treatment of HIV-1.

The multinational pharmaceutical, Merck has signed an agreement with MPP (Medicines Patent Pool) to license its intellectual property relating to the formulation of Raltegravir, the company’s integrase HIV drug. According to reports, the new agreement should clear the way for cheaper formulations which can be developed for some middle income countries. The license is royalty free, and because of the terms of Agreement, drug manufacturers from around the world can now develop the drug formulations of Raltegravir along with other novel combinations.

By following in the footsteps of some of the biggest names in the pharmaceutical industry, Merck has now actually made it possible for manufacturers to sell pediatric versions of their medication, but only in licensed countries and under the agreed terms. This deal between the company and MPP is the first of its kind and has made it easier for people who are living with HIV in developing countries to get easy access to a cheap medication that can very well save their lives.

According to reports, the whole idea behind the deal is to lower the price of the drug, by facilitating in the drug’s development, especially for third world countries, which now have a better chance at surviving HIV. The Agreement covers 92 countries and according to the MPP, 98.1% of children with HIV are living in those developing countries.

As suppliers/distributors, LGM Pharma is able to assist you in acquiring Raltegravir potassium CAS# 871038-72-1 in order to carry out clinical trials specifying new formulation, dosages and delivery systems. Rest assured, we will provide you with premium quality API products along with the continuous support of our team throughout the entire R&D process.

General Disease Facts

HIV or human immunodeficiency virus is a virus that is responsible for the AIDS pandemic. The virus comes in two strains, HIV-1 and HIV-2. The main reason for this is that each time the HIV is able to replicate itself, small changes occur which lead to the various forms of HIV. Out of the two, the most predominant virus is HIV-1, and it’s the one that is generally talked about when discussing HIV or AIDS. This strain can also be classified into four groups, the most common one of the group being ‘M’ or ‘Major’.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13 (1). Any patent infringement and resulting liability is solely at buyer risk.

Saxagliptin Hydrochloride- The Most Efficient Substitute for Insulin

Saxagliptin hydrochloride CAS: 709031-78-7

The Hyderabad-based pharmaceutical company, Lee Pharma, has recently released a statement which says that Saxagliptin hydrochloride is the most effective substitute for insulin injectables for the treatment of Type-2 diabetes.

The statement was made while Lee Pharma said that the multinational company AstraZeneca, which it applied to for the patented diabetes medication Saxagliptin hydrochloride, was unable to keep up with the demand for the patented medicine. According to reports, Lee Pharma, which is a Rs. 200 crore drug company, filed an application back in June with the Controller of Patents in Mumbai seeking the license which is compulsory for the use of Saxagliptin hydrochloride.

Lee Pharma said the reason for filing the application and the growing need for Saxagliptin hydrochloride is that the population of Type-2 diabetes in India is currently around 60 million, and there were only four key anti-diabetes medications being used with Saxagliptin hydrochloride being one of them. The spokesperson from Lee Pharma also added that if one million patients were to be prescribed Saxagliptin, it would require the manufacturer to roll out around 365 million tablets each year to keep up with the demand. Currently, Lee Pharma has three major manufacturing units in Visakhapatnam and Hyderabad. The anti-diabetic medication they manufacturer is sold both locally and is also exported to 48 countries around the world.

As suppliers/distributors, LGM Pharma can assist you in acquiring Saxagliptin Hydrochloride CAS# 945667-22-1 to carry out your clinical trials, or for new formulation of dosages. We offer our customers the best premium quality APIs, with full compliance to strict guidelines and regulated by leading authorities. Apart from that, our customers also get our expert support throughout the R&D process.

General Drug Facts

Saxagliptin hydrochloride is a dipeptidyl peptidase-4 (DPP-4) inhibitor which is commonly used for the treatment of Type-2 diabetes. It works by increasing insulin levels that are released by your body, while decreasing the amount of sugar made by the natural process in a person’s body. The drug is usually used alongside a proper diet and exercise. Saxagliptin hydrochloride can be used alone and along with other medication.

General Disease Facts

Type-2 diabetes is a chronic disease in which a person has a high level of sugar in their blood. Type-2 diabetes is one of the most common forms of diabetes and effects more people worldwide than Type-1 diabetes. Type-2 diabetes can also develop in those people who are underweight, although it usually occurs in the elderly.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

 

Linagliptin Could be the Answer to Macrovascular Complications Type-2 Diabetics

linagliptinA new study reveals that patients diagnosed with Type2-diabetes are at an increased risk of developing macrovascular and microvascular complications. Researchers are currently using a drug called Linagliptin which is an anti-diabetic drug that works by increasing the levels of incretins to help control blood sugar levels, especially after meals.

According to reports, the cardiovascular outcome trials using Linagliptin are currently being carried out and it will take a few years before the results are available. However, one well-known cardiovascular surrogate parameter is endothelial dysfunction. Research has shown that endothelial dysfunction is present in patients with early diabetes and can be improved with the help of pharmacological interventions. According to the researchers, the surrogate measurement could prove to be helpful in getting a better understanding of the cardiovascular effects of Linagliptin.

UKPDS (United Kingdom Prospective Diabetes Study) post trial monitoring highlighted the importance of an early glucose lowering intervention in patients with T2DM with respect to micro- and macrovascular complications. The aim of the study has been to further investigate the effects of Linagliptin in coronary patients who have Type-2 diabetes on cardiovascular surrogate measurements along with mechanical and biochemical endothelial assessments.

As the top suppliers of API products for the research and development of anti-diabetic drugs, LGM Pharma supplies high quality Linagliptin CAS# 668270-12-0 for future drug development studies.

General Drug Facts

Linagliptin is used along with a suitable diet and exercise program and sometimes along with other medications to control high blood sugar levels. It is normally used by those people who have been diagnosed with Type-2 diabetes. Controlling high blood sugar is important since it prevents kidney damage, nerve problems, blindness and a loss of function of limbs. Results in 2010 from a Phase III clinical trial of Linagliptin showed that it is highly effective when it comes to reducing blood sugar levels.

General Disease Facts

Type 2 diabetes is common among middle-aged and older adults, but it has also been found in younger people too. Type-2 diabetes is characterized by a high blood glucose level which is caused by either the body’s inability to use insulin properly or the lack of insulin in the body.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

LGM Pharma Representatives Attend CPhI Conference in Spain

CPhI Conference NASHVILLE, Tennessee — Representatives from LGM Pharma, a leading supplier of active pharmaceutical ingredients to various global pharmaceutical firms, headquartered in Nashville, Tennessee with administrative offices in Boca Raton, Florida, recently attended the CPhI Worldwide conference in Madrid, Spain. CPhI is the world’s leading pharmaceutical platform that brings together pharma ingredients manufacturers, suppliers and buyers. The conference agenda tackled the most timely and business critical issues facing the pharmaceutical industry today.

During the conference, representatives of LGM Pharma met with strategic manufacturers to discuss involvement in the development of commercial products. Industry updates and information were exchanged and insight into various regulatory industry intelligence was shared.

According to Mendy Schurder, LGM Director and COO, “By attending the CPhI conference, we had the opportunity to gather the latest market trends, explore key case study insights and benefit from exceptional networking opportunities all within three days. Although we had a full meeting schedule, LGM considers this the most vital venue to meet with clients, manufacturers and potential new business partners.”

“Given the limited time with each business partner, LGM was still able to have meetings with, and come away with, key commitments to some late phase development projects with a specialty pharma client in the new drug delivery space,” said Robert Hoppes, LGM Director of Sales. “Our industry experience enables us to support our clients throughout the entire pathway of drug development, from drug discovery through commercial production.”

“In today’s world, international business is easily accomplished, where everything is readily accessible and instantaneous,” stated Albert Miseje, LGM Vice president, New Business Development. “However, it’s still essential to go back to the basics and conduct face to face meetings. This value still holds true today.”

The CPhI Worldwide conference hosted over 36,000 visiting pharma professionals, 2,500 exhibitors from more than 150 countries and more than 100 industry seminars, covering every sector in four massive halls.

LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to Contract manufacturers and various global pharmaceutical firms involved in the manufacturing, research and development of a wide range of therapeutic chemical entities. In its commitment to improving health opportunities all over the world, LGM Pharma has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients.

Posaconazole as a Reliable Antifungal Therapy

Posaconazole CAS No 171228-49-2The use of Posaconazole, also known as the brand name Noxafil, continues to be a reliable and effectual therapy for fighting fungal infections. Posaconazole is FDA approved to treat fungal infections occurring in patients with weakened immune systems, like patients with HIV infection or those who are recovering from stem cell transplantation. In March 2014, the Posaconazole 18 mg/ml injection was approved as Noxafil injection, marketed by Merck, as a prophylaxis for invasive Aspergillus and Candida infections in patients ages 13 and older. This adolescent indication was welcomed by this patient population who are in need of efficacious treatment for preventing deadly fungal infections. This novel formulation for intravenous use joined Posaconazole 100 milligram delayed release tablets and 40 milligram oral suspension for the prophylaxis of invasive Aspergillus and Candida infections in patients ages 18 and older. The advent of the Posaconazole (Noxafil) injection offered an appropriate transition to oral Posaconazole treatment for patients, with a small occurrence of adverse effects. Side effects from Posaconazole reported by patients includes diarrhea, nausea and mild fever.

The delayed-release Posaconazole tablets performed exceedingly well in several comparative and multicenter studies. Both the safety and tolerability of Posaconazole was established in a variety of patients. One study involved patients with acute myeloid leukemia or myelodysplastic syndrome and who had developed (or was developing) significant neutropenia. Study participants received a once-daily dose of Posaconazole (Noxafil) delayed-release tablets, following a 300 milligram loading dose on the first day of treatment. Administration of Posaconazole with food increased the oral bioavailability of this potent product, and laboratory data revealed that the delayed-release tablets provided higher plasma drug exposures in comparison to the oral suspension.

However, Posaconazole oral suspension is also clinically effective, as proven with data from two viable studies. The aforementioned studies examined the prophylaxis of Aspergillus type infections in immunocompromised patients. Study participants in these trials were administered for prophylaxis of fungal infections with either Posaconazole, Itraconazole or Fluconazole. The patient group who received Posaconazole were given 200 milligrams of the oral suspension three times daily. This was compared with 400 milligrams of Fluconazole oral suspension once daily or Itraconazole 200 milligram oral suspension twice daily. The successful prevention of invasive fungal infections in these neutropenic patients was the goal of these studies. The clinical failure in patients was lower for the group who received Posaconazole, at 27 percent. In comparison, the patients who were administered Fluconazole and Itraconazole experienced a 42 percent clinical failure rate. As with the intravenous and delayed release tablets, adverse effects were uncommon, and included reports of nausea, diarrhea and vomiting. LGM Pharma can assist clients as a supplier/distributor of the Posaconazole API, CAS # 171228-49-2 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.